Analysts predict that CELLECT BIOTECH / S (APOP) will display – $ 0.29 EPS



[ad_1]

  CELLECT BIOTECH / S logo "title =" CELLECT BIOTECH / S logo "clbad =" companylogo "/> Wall Street brokerage firms predict that CELLECT BIOTECH / S (NASDAQ: APOP) will post earnings per share of $ 0.29) According to Zacks, Zero badysts have estimated the profit of CELLECT BIOTECH / S.CELLECT BIOTECH / S posted earnings per share of ($ 0.23) in the same quarter last year , which would indicate a year The company is expected to announce its next quarterly results on Monday, August 20. </p>
<p>  According to Zacks, badysts expect CELLECT BIOTECH / S to announce an annual profit of ($ 1.00) per share For the current fiscal year, badysts expect the company to post a profit of ($ 1.17) per share. Zacks EPS calculations are an average based on a survey of badysts who follow CELLECT BIOTECH / S. [19659003] CELLECT BIOTECH / S (NASDAQ: APOP) published for the last time is his e arnings data on Thursday May 17th. The company reported ($ 0.16) EPS for the quarter, leading consensus ($ 0.30) of $ 0.14. </p>
<p>Several equity research badysts recently commented on APOP shares. Zacks Investment Research upgraded CELLECT BIOTECH / S shares from a "hold" rating to a "buy" rating and set a price target of $ 8.00 on the stock in a research note on Tuesday, March 20 . HC Wainwright reissued a "buy" note and set a price target of $ 14.00 on CELLECT BIOTECH / S shares in a research note on Tuesday, May 29. Finally, ValuEngine has updated the shares of CELLECT BIOTECH / S from a "sale" rating to a "sustain" rating in a research note on Wednesday, June 6th.</p>
<p> An institutional investor recently bought a new position in CELLECT BIOTECH shares / S. Sabby Management LLC acquired a new stake in CELLECT BIOTECH / S shares (NASDAQ: APOP) in the first quarter, according to its most recent Form 13F filed with the Securities & Exchange Commission. The fund acquired 243,980 shares of the Company, valued at approximately $ 1,557,000. CELLECT BIOTECH / S represents approximately 0.2% of the investment portfolio of Sabby Management LLC, which places the stock at 23rd of its capital. Sabby Management LLC held approximately 4.48% of CELLECT BIOTECH / S since its last filing with the Securities & Exchange Commission. Institutional investors own 6.22% of the company's shares. </p>
<p>  NASDAQ: APOP traded up $ 0.01 in mid-day Friday, reaching $ 7.21. 14,346 shares of the company were exchanged, compared with an average volume of 6,176 shares. CELLECT BIOTECH / S has a minimum of one year of $ 6.12 and a one – year high of $ 13.50. The company has a market capitalization of $ 39.17 million, a price / earnings ratio of -4.94 and a beta of 4.68. </p>
<p>  <strong> About CELLECT BIOTECH / S </strong> </p>
<p>  Cellect Biotechnology Ltd., a biotechnology company, focuses on the development of technologies for the functional selection of stem cells in the field of regenerative medicine and cell therapies in Israel. He is developing the Apotainer Selection Kit, a stem cell selection kit on the shelf, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures in patients with hematological tumors. <!--ViewCount:ArticleHistoryID=21125100&PostDate=2018-7-7&type=c&id=427320--> <!--Keyword: CELLECT BIOTECH/S,NASDAQ:APOP,APOP,Medical,Ratings,Consensus--> <!--Ratings:4,1,NASDAQ:APOP--> </p>
<p>  A Free Copy of the Zacks Research Report on CELLECT BIOTECH / S (APOP) </p>
<p>  For more information on Zacks Investment Research's research opportunities, visit Zacks.com </p>
<p>			 	<!-- end inline unit --><br />
				<!-- end main text --><br />
				<!-- Invalidate Article --></p>
<p>				<!-- End Invalidate --></p>
<p><!--Begin Footer Opt-In--></p>
<p style= Receive news and ratings for CELLECT BIOTECH / S Daily – Enter your email address below to receive a concise daily summary of the latest news and badyst ratings for CELLECT BIOTECH / S and related companies with MarketBeat.com's FREE Daily E-newsletter.

[ad_2]
Source link